Serological markers of recurrent beta cell destruction in diabetic patients undergoing pancreatic transplantation.

BACKGROUND Besides alloimmunity to transplanted pancreatic tissue, recurrent autoimmune beta cell destruction is an additional limitation to successful clinical pancreatic allografts in type 1 diabetic patients. METHODS We studied the prevalence of autoantibodies to glutamate decarboxylase (GAD) 65 and tyrosine phosphatase (IA-2) in 68 C-peptide-negative diabetic patients receiving pancreatic allografts. Sera from patients were obtained immediately before grafting. A second blood sample was analyzed at the time of graft failure in patients who returned to hyperglycemia and during the same follow-up period in those who experienced a functional pancreatic allograft. Patients were classified according to clinical outcome into chronic graft failure (group A, n=20), acute graft failure and/or arterial thrombosis (n=7), or functional pancreatic graft (group C, n=41). Sera from patients were screened for the presence of specific autoantibodies using an islet cell autoantibody assay, a combi-GAD and IA-2 test, and individual GAD and IA-2 assays. RESULTS Patients from group A had significantly higher combi-test values than patients from group C (13+/-16 vs. 4.5+/-12 units, P<0.02) and higher anti-GAD65 antibody (Ab) levels (0.19+/-0.3 vs. 0.04+/-0.13 units, P<0.01) immediately before grafting. After graft failure in group A, both anti-GAD65 and anti-IA-2 Ab levels increased from baseline, but only the increase in anti-IA-2 Ab levels reached statistical significance (0.28+/-0.12 vs. 15+/-34, P=0.03). When compared with group C, patients from group A had higher anti-GAD65 Abs (0.29+/-0.35 vs. 0.05+/-0.16, P<0.001) after graft failure. Interestingly, the number of double-Ab-positive patients rose from 5% to 35% in group A, whereas it remained at 5% in group C. In pancreatic transplants with bladder drainage, the presence of anti-GAD65 and/or anti-IA2 Abs was not associated with a reduction in urinary amylase levels. This suggests that a loss of endocrine function was not associated with exocrine failure in patients from group A. CONCLUSIONS We can conclude from the present study that peripheral autoimmune markers are useful in diabetic patients receiving pancreatic allografts.

[1]  D. Sutherland,et al.  Report from the International Pancreas Transplant Registry--1998. , 1999, Transplantation proceedings.

[2]  C. Thivolet,et al.  Pancreas transplantation: results and indications. , 1998, Diabetes & metabolism.

[3]  B. Hering,et al.  Progressive Islet Graft Failure Occurs Significantly Earlier in Autoantibody-Positive Than in Autoantibody-Negative IDDM Recipients of Intrahepatic Islet Allografts , 1997, Diabetes.

[4]  F. Reinholt,et al.  Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. , 1996, The New England journal of medicine.

[5]  A. Ziegler,et al.  Perinatal Autoimmunity in Offspring of Diabetic Parents: The German Multicenter BABY-DIAB Study: Detection of Humoral Immune Responses to Islet Antigens in Early Childhood , 1996, Diabetes.

[6]  H. Chase,et al.  Prediction of Type I Diabetes in First-Degree Relatives Using a Combination of Insulin, GAD, and ICA512bdc/IA-2 Autoantibodies , 1996, Diabetes.

[7]  M. Lan,et al.  IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Stegall,et al.  Evidence of recurrent autoimmunity in human allogeneic islet transplantation. , 1996, Transplantation.

[9]  M. Christie,et al.  Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). , 1995, The Journal of clinical investigation.

[10]  J. Petersen,et al.  Detection of GAD65 Antibodies in Diabetes and Other Autoimmune Diseases Using a Simple Radioligand Assay , 1994, Diabetes.

[11]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[12]  E. Bonifacio,et al.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes , 1990, The Lancet.

[13]  D. Sutherland,et al.  Recurrence of Disease in Pancreas Transplants , 1989, Diabetes.

[14]  A. Gelet,et al.  Islet Cell Autoimmunity in Type I Diabetic Patients After HLA-Mismatched Pancreas Transplantation , 1989, Diabetes.

[15]  Y. Mullen,et al.  Allogeneic and syngeneic pancreas transplantation in non-obese diabetic mice. , 1987, Transplantation proceedings.

[16]  D. Bellgrau,et al.  Islet Allografts Are Destroyed by Disease Occurrence in the Spontaneously Diabetic BB Rat , 1986, Diabetes.

[17]  A. Like,et al.  Immune attack on pancreatic islet transplants in the spontaneously diabetic BioBreeding/Worcester (BB/W) rat is not MHC restricted. , 1985, Journal of immunology.

[18]  W. Gepts.  Pathologic Anatomy of the Pancreas in Juvenile Diabetes Mellitus , 1965, Diabetes.

[19]  B. Hering,et al.  Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression , 1999, Journal of Molecular Medicine.

[20]  G. Eisenbarth,et al.  Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. , 1990, Annual review of immunology.

[21]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[22]  A. Michael,et al.  Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. , 1984, Transactions of the Association of American Physicians.